a Unit of Clinical Pharmacology , AOU Policlinico "G. Martino" , Messina , Sicily , Italy.
b Department of Biomedical and Dental Sciences and Morphofunctional Imaging , University of Messina , Messina , Sicily , Italy.
Expert Opin Drug Saf. 2018 Jul;17(7):681-695. doi: 10.1080/14740338.2018.1491547. Epub 2018 Jul 3.
Adverse drug reactions (ADRs) are an important cause of morbidity and mortality worldwide. They are associated with healthcare costs due to hospital admissions or prolonged length of stay, as well as additional interventions. The aim of this study was to conduct a systematic review of observational studies to evaluate the economic impact of preventable ADRs.
Published observational research investigating the cost of preventable ADRs in Western countries (limited to the USA and European countries).
Several reviews have been carried out in the field of the ADR epidemiology but fewer reviews have investigated the economic impact of ADRs, and at the time of writing, none has focused on preventable ADRs. The reason why future research should focus on the costs of preventable ADRs is that both the costs and the negative clinical outcomes are preventable, and as such, are a key point of public health policy action. Nevertheless, the present review highlights an important and sobering limitation of published research on the cost of preventable ADRs, of which the major limitation is the heterogeneity in methods and in reporting which limit what can be known through the summarizing work of a systematic review.
药物不良反应（ADR）是全球发病率和死亡率的重要原因。由于住院或住院时间延长，以及额外的干预措施，ADR 与医疗保健成本有关。本研究旨在对观察性研究进行系统评价，以评估可预防 ADR 的经济影响。
已发表的观察性研究，调查了西方国家（限于美国和欧洲国家）可预防 ADR 的成本。
在药物不良反应流行病学领域已经进行了几项综述，但对药物不良反应的经济影响进行的综述较少，而且在撰写本文时，还没有专门针对可预防 ADR 的综述。未来的研究应该关注可预防 ADR 的成本的原因是，成本和负面临床结果都是可预防的，因此，是公共卫生政策行动的关键点。然而，本综述突出了已发表的关于可预防 ADR 成本的研究的一个重要且令人警醒的局限性，其主要局限性在于方法和报告的异质性，限制了通过系统评价的总结工作所了解的内容。
